[go: up one dir, main page]

WO2006027567A3 - Administration de medicaments a partir d'agents d'embolisation - Google Patents

Administration de medicaments a partir d'agents d'embolisation Download PDF

Info

Publication number
WO2006027567A3
WO2006027567A3 PCT/GB2005/003431 GB2005003431W WO2006027567A3 WO 2006027567 A3 WO2006027567 A3 WO 2006027567A3 GB 2005003431 W GB2005003431 W GB 2005003431W WO 2006027567 A3 WO2006027567 A3 WO 2006027567A3
Authority
WO
WIPO (PCT)
Prior art keywords
anionic
drug delivery
ethylenically unsaturated
polyvinylalcohol
crosslinked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003431
Other languages
English (en)
Other versions
WO2006027567A2 (fr
Inventor
Andrew Lennard Lewis
Peter William Stratford
Maria Victori Gonzalez-Fajardo
Yiqing Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocompatibles UK Ltd
Original Assignee
Biocompatibles UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007529390A priority Critical patent/JP5221134B2/ja
Priority to US11/574,703 priority patent/US20070275991A1/en
Priority to AU2005281483A priority patent/AU2005281483B2/en
Priority to DE602005027477T priority patent/DE602005027477D1/de
Priority to AT05777645T priority patent/ATE505185T1/de
Priority to EP05777645A priority patent/EP1796644B1/fr
Priority to CA2579533A priority patent/CA2579533C/fr
Application filed by Biocompatibles UK Ltd filed Critical Biocompatibles UK Ltd
Publication of WO2006027567A2 publication Critical patent/WO2006027567A2/fr
Publication of WO2006027567A3 publication Critical patent/WO2006027567A3/fr
Anticipated expiration legal-status Critical
Priority to US13/282,953 priority patent/US20120276151A1/en
Priority to US13/452,493 priority patent/US20120201867A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne une composition d'embolisation comprenant des microsphères constituées d'un polymère anionique insoluble dans l'eau, capable de gonfler dans l'eau et présentant, à l'état gonflé, un diamètre supérieur à 100 µm, et d'un composé de camptothécine cationique, de préférence d'irinotécane. Ces microsphères sont de préférence constituées d'alcool polyvinylique réticulé, de préférence de macromère d'alcool polyvinylique éthyléniquement insaturé, réticulé avec un comonomère anionique éthyléniquement insaturé. Ces compositions sont utilisées pour traiter des tumeurs hypervasculaires, par exemple des métastases hépatiques colorectales.
PCT/GB2005/003431 2004-09-07 2005-09-06 Administration de medicaments a partir d'agents d'embolisation Ceased WO2006027567A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US11/574,703 US20070275991A1 (en) 2004-09-07 2005-09-06 Drug Delivery From Embolic Agents
AU2005281483A AU2005281483B2 (en) 2004-09-07 2005-09-06 Drug delivery from embolic agents
DE602005027477T DE602005027477D1 (de) 2004-09-07 2005-09-06 Arzneimittelabgabe aus embolischen mitteln
AT05777645T ATE505185T1 (de) 2004-09-07 2005-09-06 Arzneimittelabgabe aus embolischen mitteln
EP05777645A EP1796644B1 (fr) 2004-09-07 2005-09-06 Administration d'un médicament à partir d'agents emboliques
JP2007529390A JP5221134B2 (ja) 2004-09-07 2005-09-06 塞栓剤からの薬物送達
CA2579533A CA2579533C (fr) 2004-09-07 2005-09-06 Administration de medicaments a partir d'agents d'embolisation
US13/282,953 US20120276151A1 (en) 2004-09-07 2011-10-27 Drug delivery from embolic agents
US13/452,493 US20120201867A1 (en) 2004-09-07 2012-04-20 Drug delivery from embolic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04255411 2004-09-07
EP04255411.3 2004-09-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/282,953 Division US20120276151A1 (en) 2004-09-07 2011-10-27 Drug delivery from embolic agents

Publications (2)

Publication Number Publication Date
WO2006027567A2 WO2006027567A2 (fr) 2006-03-16
WO2006027567A3 true WO2006027567A3 (fr) 2006-05-18

Family

ID=34930630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003431 Ceased WO2006027567A2 (fr) 2004-09-07 2005-09-06 Administration de medicaments a partir d'agents d'embolisation

Country Status (11)

Country Link
US (3) US20070275991A1 (fr)
EP (3) EP2269580A3 (fr)
JP (4) JP5221134B2 (fr)
CN (2) CN101052378A (fr)
AT (1) ATE505185T1 (fr)
AU (1) AU2005281483B2 (fr)
CA (1) CA2579533C (fr)
DE (1) DE602005027477D1 (fr)
ES (1) ES2361919T3 (fr)
HK (1) HK1198691A1 (fr)
WO (1) WO2006027567A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397593A (zh) * 2011-11-11 2012-04-04 北京大学 X线下可显影的栓塞微粒及其制备方法和应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872884B1 (ko) 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
WO2006013376A2 (fr) * 2004-08-04 2006-02-09 Biocompatibles Uk Limited Liberation de medicaments a partir d'agents emboliques
EP2484344B1 (fr) 2005-05-09 2016-02-10 Biosphere Medical, S.A. Compositions et procédés pour utiliser des microsphères et des agents de contraste non ioniques
ES2403645T5 (es) * 2006-06-22 2020-11-16 Biocompatibles Uk Ltd Producto farmacéutico rehidratable
EP1985286A1 (fr) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microsphères pour le traitement de tumeurs cérébrales
ES2706023T3 (es) * 2007-08-16 2019-03-27 Biocompatibles Uk Ltd Administración de combinaciones de fármacos
EP2367535B1 (fr) * 2008-12-02 2017-02-22 Biocompatibles Uk Ltd. Traitement de tumeur du pancréas
ES2542242T3 (es) * 2010-11-29 2015-08-03 Centre Hospitalier Universitaire Vaudois Composición de quimioembolización que comprende agentes antiangiogénicos
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
CN102336904B (zh) * 2011-09-29 2013-03-27 成都一平医药科技发展有限公司 一种喜树碱及其衍生物的多价peg修饰物及其用途
HRP20171364T1 (hr) * 2012-11-15 2017-11-03 Utah-Inha Dds & Advanced Therapeutics Research Center Biorazgradive mikrogranule s poboljšanim kapacitetom adsorpcije lijekova protiv raka, koji sadržava albumin i dekstran sulfat, i postupak njihove pripreme
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
CN104994841B (zh) 2012-11-27 2018-11-16 犹他-仁荷Dds及新医疗技术开发共同研究所 包含阴离子性高分子的抗癌药吸附能力得到提高的生物降解性微珠及其的制备方法
EP3046952B1 (fr) 2013-09-19 2021-05-12 Terumo Corporation Particules polymères
JP6641265B2 (ja) 2013-09-19 2020-02-05 マイクロベンション インコーポレイテッドＭｉｃｒｏｖｅｎｔｉｏｎ， Ｉｎｃ． ポリマーフィルム
CN105916495B (zh) 2013-11-08 2019-11-12 泰尔茂株式会社 聚合物颗粒
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
JP2016124818A (ja) * 2014-12-26 2016-07-11 日本化薬株式会社 転移性肝癌治療薬及び転移性肝癌の治療方法
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
WO2016203337A2 (fr) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions et méthodes de traitement du cancer
WO2016203352A2 (fr) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions et méthodes de traitement du cancer
GB201515602D0 (en) 2015-09-03 2015-10-21 Biocompatibles Uk Ltd Polymers and microspheres
CA3038719C (fr) 2016-09-28 2020-04-21 Terumo Corporation Particules polymeres
CN111315368A (zh) 2017-05-26 2020-06-19 布鲁因生物科学公司 化学栓塞剂
CN107812232A (zh) * 2017-11-08 2018-03-20 华威（深圳）医疗器械有限责任公司 可显影羧基改性聚乙烯醇微球栓塞剂及其制备工艺
EP3888708B1 (fr) * 2018-11-30 2024-01-03 Nextbiomedical Co., Ltd. Particules d'hydrogel pour chimioembolisation comprenant un polymère biodégradable
GB201918300D0 (en) * 2019-12-12 2020-01-29 Extruded Pharmaceuticals Ltd Chemotherapeutic drug implant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071495A1 (fr) * 2003-02-12 2004-08-26 Biocompatibles Uk Limited Composition utilisee dans la chimio-embolotherapie de tumeurs solides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032561A (en) * 1975-05-27 1977-06-28 The Upjohn Company 17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGF1.sub.α compounds
US4224427A (en) 1978-06-01 1980-09-23 Ciba-Geigy Corporation Process for preparing hydrogels as spherical beads of large size
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4978713A (en) 1987-12-16 1990-12-18 Ciba-Geigy Corporation Polyvinyl alcohol derivatives containing pendant vinylic monomer reaction product units bound through ether groups and hydrogel contact lenses made therefrom
GB9023498D0 (en) 1990-10-29 1990-12-12 Biocompatibles Ltd Soft contact lens material
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
GB9301702D0 (en) 1993-01-28 1993-03-17 Biocompatibles Ltd New materials
GB9301701D0 (en) 1993-01-28 1993-03-17 Biocompatibles Ltd New zwitterionic materials
TW272976B (fr) 1993-08-06 1996-03-21 Ciba Geigy Ag
GB9415926D0 (en) 1994-08-04 1994-09-28 Biocompatibles Ltd New materials
CA2192725C (fr) * 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
ES2212648T3 (es) 1998-11-13 2004-07-16 Biocompatibles Uk Limited Complejo de poliiones anionicos-cationicos que comprenden un componente monomero dipolar.
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DE19905639A1 (de) * 1999-02-11 2000-08-17 Clariant Gmbh Wasserlösliche oder wasserquellbare Polymerisate
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US7838699B2 (en) * 2002-05-08 2010-11-23 Biosphere Medical Embolization using degradable crosslinked hydrogels
DE10230991A1 (de) 2002-07-10 2004-02-12 Robert Bosch Gmbh Werkzeugaufnahme für eine Werkzeugmaschine
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US20040161466A1 (en) * 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071495A1 (fr) * 2003-02-12 2004-08-26 Biocompatibles Uk Limited Composition utilisee dans la chimio-embolotherapie de tumeurs solides

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; April 1990 (1990-04-01), WU X J: "[An experimental study of the basic properties of drug microspheres and target treatment of rats with liver tumor]", XP002315407, Database accession no. NLM2379445 *
ERTL B ET AL: "Poly(d,l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 61, no. 3, 20 September 1999 (1999-09-20), pages 305 - 317, XP004362985, ISSN: 0168-3659 *
HATEFI A ET AL: "Camptothecin delivery methods.", PHARMACEUTICAL RESEARCH (DORDRECHT), vol. 19, no. 10, October 2002 (2002-10-01), pages 1389 - 1399, XP002315406, ISSN: 0724-8741 *
MACHIDA Y ET AL: "Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 66, no. 2-3, May 2000 (2000-05-01), pages 159 - 175, XP004193065, ISSN: 0168-3659 *
SAENGER JAN ET AL: "Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. APR 2004, vol. 130, no. 4, April 2004 (2004-04-01), pages 203 - 210, XP002315404, ISSN: 0171-5216 *
SHENDEROVA A ET AL: "STABILIZATION OF 10-HYDROXYCAMPTOTHECIN IN POLY(LACTIDE-CO- GLYCOLIDE) MICROSPHERE DELIVERY VEHICLES", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 14, no. 10, 1997, pages 1406 - 1414, XP000874396, ISSN: 0724-8741 *
SPENLEHAUER G ET AL: "Formation and characterization of cisplatin loaded poly(d,l-lactide) microspheres for chemoembolization.", JOURNAL OF PHARMACEUTICAL SCIENCES. AUG 1986, vol. 75, no. 8, August 1986 (1986-08-01), pages 750 - 755, XP002315405, ISSN: 0022-3549 *
YOSHIZAWA HIDEKAZU ET AL: "Surface morphology change of polylactide microspheres enclosing irinotecan hydrochloride and its effect on release properties", J. CHEM. ENG. JPN.; JOURNAL OF CHEMICAL ENGINEERING OF JAPAN OCTOBER 2003, vol. 36, no. 10, October 2003 (2003-10-01), pages 1206 - 1211, XP002372734 *
ZHONGHUA WAI KE ZA ZHI [CHINESE JOURNAL OF SURGERY]. APR 1990, vol. 28, no. 4, April 1990 (1990-04-01), pages 241 - 243 , 254, ISSN: 0529-5815 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397593A (zh) * 2011-11-11 2012-04-04 北京大学 X线下可显影的栓塞微粒及其制备方法和应用

Also Published As

Publication number Publication date
EP3085361A1 (fr) 2016-10-26
JP2015180625A (ja) 2015-10-15
US20070275991A1 (en) 2007-11-29
ATE505185T1 (de) 2011-04-15
JP2012236840A (ja) 2012-12-06
JP5221134B2 (ja) 2013-06-26
CN103860479A (zh) 2014-06-18
EP2269580A3 (fr) 2011-11-09
HK1198691A1 (en) 2015-05-29
JP5792691B2 (ja) 2015-10-14
AU2005281483B2 (en) 2008-11-27
EP1796644B1 (fr) 2011-04-13
DE602005027477D1 (de) 2011-05-26
ES2361919T3 (es) 2011-06-24
EP1796644A2 (fr) 2007-06-20
US20120276151A1 (en) 2012-11-01
CN101052378A (zh) 2007-10-10
WO2006027567A2 (fr) 2006-03-16
JP2008512370A (ja) 2008-04-24
CA2579533C (fr) 2013-05-21
CA2579533A1 (fr) 2006-03-16
US20120201867A1 (en) 2012-08-09
JP2017025071A (ja) 2017-02-02
AU2005281483A1 (en) 2006-03-16
EP2269580A2 (fr) 2011-01-05

Similar Documents

Publication Publication Date Title
WO2006027567A3 (fr) Administration de medicaments a partir d'agents d'embolisation
WO2008057163A3 (fr) Préparation de particules de gel fonctionnelles avant un réseau réticulé double
WO2003009881A3 (fr) Nouveaux systemes d'administration ciblee pour agents bioactifs
WO2004093795A3 (fr) Compositions d'administration de combinaisons de medicaments
WO2006044502A3 (fr) Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
WO2006017852A3 (fr) Compositions pharmaceutiques permettant la liberation progressive de composes bioactifs
WO2007109244A3 (fr) Nouvelles nanoparticules destinees a la delivrance d'agents actifs
WO2005058366A3 (fr) Compositions contenant deux populations diffferentes de conjugues polymeres-agents actifs
WO2004004683A8 (fr) Dispersions solides comprenant deux matrices polymeriques distinctes
WO2004089942A3 (fr) Derives de benzimidazolidinone utilises en tant qu'agents muscariniques
WO2003028696A8 (fr) Compositions pour l'administration de combinaisons medicinales
WO2005120466A3 (fr) Enrobages drageifies et procedes permettant de produire ces enrobages drageifies
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2007150074A3 (fr) Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée
WO2005042600A3 (fr) Polymeres de poids moleculaire eleve, dispositifs et procede de production et utilisation
WO2005097064A3 (fr) Medicaments au gout masque lors de la rupture des matieres particulaires multiples
WO2003057716A3 (fr) Encapsulation dendritique d'agents actifs
WO2003074033A8 (fr) Formulation solide a liberation prolongee/controlee en tant que nouveau systeme d'administration de medicaments a risque reduit de liberation massive
WO2007133944A3 (fr) Administration topique d'acyclovir
WO2007100822A3 (fr) Compositions pharmaceutiques de fluvastatine sodique
WO2002030399A3 (fr) Liberation d'agent therapeutique controlee par polymere
WO2006128796A3 (fr) Compositions polymeres contenant des polyolefines et des copolymeres sequences amphiphiles ainsi qu'eventuellement d'autres polymeres et/ou des charges et procedes pour colorer de telles compositions ou realiser une impression sur ces dernieres
AU2003256882A8 (en) Methods of drug delivery using sulphated chitinous polymers
WO2007067752A3 (fr) Compositions et procedes de traitement
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005777645

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005281483

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2579533

Country of ref document: CA

Ref document number: 2007529390

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005281483

Country of ref document: AU

Date of ref document: 20050906

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005281483

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580037469.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11574703

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005777645

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11574703

Country of ref document: US